INOGEN, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.91 USD | +3.13% |
|
-0.29% | +25.87% |
| Feb. 28 | Top Midday Decliners | MT |
| Feb. 28 | Top Premarket Decliners | MT |
Financials (USD)
| Sales 2024 * | 324M | Sales 2025 * | 338M | Capitalization | 158M |
|---|---|---|---|---|---|
| Net income 2024 * | -57M | Net income 2025 * | -51M | EV / Sales 2024 * | 0.24 x |
| Net cash position 2024 * | 78.92M | Net cash position 2025 * | 54.47M | EV / Sales 2025 * | 0.31 x |
| P/E ratio 2024 * |
-2.68
x | P/E ratio 2025 * |
-3.43
x | Employees | 834 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.16% |
More Fundamentals
* Assessed data
More news
Latest transcript on Inogen, Inc.
More recommendations
More press releases
| 1 day | +1.34% | ||
| 1 week | -4.18% | ||
| Current month | -17.72% | ||
| 1 month | -11.70% | ||
| 3 months | +20.95% | ||
| 6 months | +49.89% | ||
| Current year | +20.95% |
1 week
6.62
7.28
1 month
6.148.19
Current year
5.0810.64
1 year
4.1314.10
3 years
4.1382.35
5 years
4.1395.59
10 years
4.13287.79
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Smith
CEO | Chief Executive Officer | 53 | Nov. 09 |
Stanislav Glezer
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-06-20 |
| Human Resources Officer | - | 22-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kevin King
BRD | Director/Board Member | 67 | 22-03-21 |
Thomas West
BRD | Director/Board Member | 60 | 23-03-31 |
Heather Rider
BRD | Director/Board Member | 65 | 14-08-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.19% | 27 M€ | -5.28% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 6.91 | +3.13% | 184 495 |
| 24-04-22 | 6.7 | -0.74% | 173,383 |
| 24-04-19 | 6.75 | -4.80% | 260,842 |
| 24-04-18 | 7.09 | +2.01% | 346,206 |
| 24-04-17 | 6.95 | +0.29% | 464,068 |
Delayed Quote Nasdaq, April 23, 2024 at 09:31 am EDT
More quotes
Inogen, Inc. is a medical technology company offering respiratory products for use in the homecare setting. The Company supports patient respiratory care by developing, manufacturing, and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its Inogen One and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. Its Inogen One systems reduces patients' reliance on stationary concentrators and oxygen compressed gas tanks. Its Inogen Connect is a wireless connectivity platform for the Inogen One G4, Inogen One G5 and Rove 6 consisting of a front-end mobile application for use by long-term oxygen therapy users and a back-end database portal for use by homecare providers. It also offers Simeox, which is an airway clearance device.
Calendar
2024-05-06
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
6.7
USD
Average target price
6.5
USD
Spread / Average Target
-2.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.95% | 158M | |
| -2.73% | 186B | |
| -2.00% | 107B | |
| -3.71% | 67.57B | |
| +5.89% | 50.7B | |
| +15.21% | 47.2B | |
| -0.45% | 39.72B | |
| +7.39% | 27.48B | |
| +0.76% | 25.65B | |
| +13.37% | 24.97B |
- Stock Market
- Equities
- INGN Stock
